BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 25414443)

  • 41. Targeting CD79b for Chimeric Antigen Receptor T-Cell Therapy of B-Cell Lymphomas.
    Ding S; Mao X; Cao Y; Wang N; Xu H; Zhou J
    Target Oncol; 2020 Jun; 15(3):365-375. PubMed ID: 32495161
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Determination of HLA-B7 T-cell epitopes.
    Freese A; Zavazava N
    Transpl Int; 1996; 9 Suppl 1():S352-5. PubMed ID: 8959863
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hepatitis E Virus (HEV)-Specific T Cell Receptor Cross-Recognition: Implications for Immunotherapy.
    Soon CF; Zhang S; Suneetha PV; Antunes DA; Manns MP; Raha S; Schultze-Florey C; Prinz I; Wedemeyer H; Sällberg Chen M; Cornberg M
    Front Immunol; 2019; 10():2076. PubMed ID: 31552033
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors.
    Thokala R; Olivares S; Mi T; Maiti S; Deniger D; Huls H; Torikai H; Singh H; Champlin RE; Laskowski T; McNamara G; Cooper LJ
    PLoS One; 2016; 11(8):e0159477. PubMed ID: 27548616
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preclinical Strategies to Identify Off-Target Toxicity of High-Affinity TCRs.
    Bijen HM; van der Steen DM; Hagedoorn RS; Wouters AK; Wooldridge L; Falkenburg JHF; Heemskerk MHM
    Mol Ther; 2018 May; 26(5):1206-1214. PubMed ID: 29567312
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Allo-HLA-reactive T cells inducing graft-versus-host disease are single peptide specific.
    Amir AL; van der Steen DM; Hagedoorn RS; Kester MG; van Bergen CA; Drijfhout JW; de Ru AH; Falkenburg JH; van Veelen PA; Heemskerk MH
    Blood; 2011 Dec; 118(26):6733-42. PubMed ID: 21972290
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.
    Myklebust JH; Brody J; Kohrt HE; Kolstad A; Czerwinski DK; Wälchli S; Green MR; Trøen G; Liestøl K; Beiske K; Houot R; Delabie J; Alizadeh AA; Irish JM; Levy R
    Blood; 2017 Feb; 129(6):759-770. PubMed ID: 28011673
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
    Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN
    Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cytotoxic activity and lymphokine production of T cell receptor (TCR)-alpha beta+ and TCR-gamma delta+ cytotoxic T lymphocyte (CTL) clones recognizing HLA-A2 and HLA-A2 mutants. Recognition of TCR-gamma delta+ CTL clones is affected by mutations at positions 152 and 156.
    Spits H; Paliard X; Engelhard VH; de Vries JE
    J Immunol; 1990 Jun; 144(11):4156-62. PubMed ID: 2111341
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mixed functional characteristics correlating with TCR-ligand koff -rate of MHC-tetramer reactive T cells within the naive T-cell repertoire.
    Hombrink P; Raz Y; Kester MG; de Boer R; Weißbrich B; von dem Borne PA; Busch DH; Schumacher TN; Falkenburg JH; Heemskerk MH
    Eur J Immunol; 2013 Nov; 43(11):3038-50. PubMed ID: 23893393
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
    Aldoss I; Bargou RC; Nagorsen D; Friberg GR; Baeuerle PA; Forman SJ
    Leukemia; 2017 Apr; 31(4):777-787. PubMed ID: 28028314
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CD19 chimeric antigen receptor T cell therapy for the treatment of B cell lineage acute lymphoblastic leukemia.
    Chen R; Song XT; Chen B
    Discov Med; 2015 Oct; 20(110):185-90. PubMed ID: 26562471
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chimeric antigen receptor T-cell immunotherapy tackles blood cancers.
    Brower V
    J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25838441
    [No Abstract]   [Full Text] [Related]  

  • 54. MDM2 is recognized as a tumor-associated antigen in chronic lymphocytic leukemia by CD8+ autologous T lymphocytes.
    Mayr C; Bund D; Schlee M; Bamberger M; Kofler DM; Hallek M; Wendtner CM
    Exp Hematol; 2006 Jan; 34(1):44-53. PubMed ID: 16413390
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
    Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
    Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Differential expression of B29 (CD79b) and mb-1 (CD79a) proteins in acute lymphoblastic leukaemia.
    Astsaturov IA; Matutes E; Morilla R; Seon BK; Mason DY; Farahat N; Catovsky D
    Leukemia; 1996 May; 10(5):769-73. PubMed ID: 8656670
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Selection of a Clinical Lead TCR Targeting Alpha-Fetoprotein-Positive Liver Cancer Based on a Balance of Risk and Benefit.
    Luo X; Cui H; Cai L; Zhu W; Yang WC; Patrick M; Zhu S; Huang J; Yao X; Yao Y; He Y; Ji Y
    Front Immunol; 2020; 11():623. PubMed ID: 32425926
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Expression of Ig-beta (CD79b) by chronic lymphocytic leukemia B cells that lack immunoglobulin heavy-chain allelic exclusion.
    Rassenti LZ; Kipps TJ
    Blood; 2000 Apr; 95(8):2725-7. PubMed ID: 10753858
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Chimeric antigen receptor T-cell therapy for ALL.
    Maude SL; Shpall EJ; Grupp SA
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):559-64. PubMed ID: 25696911
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection.
    Eyquem J; Mansilla-Soto J; Giavridis T; van der Stegen SJ; Hamieh M; Cunanan KM; Odak A; Gönen M; Sadelain M
    Nature; 2017 Mar; 543(7643):113-117. PubMed ID: 28225754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.